ACS Medicinal Chemistry Letters · 2017 · 25 citations · 27 references
MedicineMicrobiologyPharmacologyAntimicrobial PharmacologyAntimicrobial ResistanceDrug DiscoveryAntibacterial PharmacologyAntifungal AgentsAntifungal PharmacologyAntifungal ResistanceAntifungal TherapyCombination Antimicrobial TherapyAzole Antifungal InteractionsCandida Albicans InfectionCombination Antifungal TherapyEnhancersFluconazole TherapyNew Antifungal AgentsNovel Antifungal Drug DevelopmentResistance In Clinical Isolates
Four phthalazinones (CIDs 22334057, 22333974, 22334032, 22334012) and one isoquinolone (CID 5224943) were previously shown to be potent enhancers of antifungal activity of fluconazole against Candida albicans. Several even more potent analogues of these compounds were identified, some with EC50 as low as 1 nM, against C. albicans. The compounds exhibited pharmacological synergy (FIC < 0.5) with fluconazole. The compounds were also shown to enhance the antifungal activity of isavuconazole, a recently FDA approved azole antifungal. Isoquinolone 15 and phthalazinone 24 were shown to be active against several resistant clinical isolates of C. albicans.
27
The National Center for Biotechnology Information
D. A. Benson, Mark S. Boguski, David J. Lipman et al. · Genomics · 1990 · 5.2K citations · Full text
Guilhem Janbon, Kate L. Ormerod, Damien Paulet et al. · PLoS Genetics · 2014 · 410 citations · Full text
Chiatogu Onyewu, Jill R. Blankenship, Maurizio Del Poeta et al. · Antimicrobial Agents and Chemotherapy · 2003 · 284 citations · Full text
Stephanie A. Flowers, Katherine S. Barker, Elizabeth L. Berkow et al. · Eukaryotic Cell · 2012 · 239 citations · Full text